'Micro' livers could aid drug screening

MIT researchers have devised a novel way to create tiny colonies of living human liver cells that model the full-sized organ. The work could allow better screening of new drugs that are potentially harmful to the liver and reduce the costs associated with their development.

Liver toxicity is one of the main reasons pharmaceutical companies pull drugs off the market. These dangerous drugs slip through approval processes due in part to the shortcomings of liver toxicity tests. Existing tests rely on liver cells from rats, which do not always respond to toxins the way human cells do. Or they rely on dying human cells that survive for only a few days in the lab.

The new technology arranges human liver cells into tiny colonies only 500 micrometers (millionths of a meter) in diameter that act much like a real liver and survive for up to six weeks.

Sangeeta Bhatia, associate professor in the Harvard-MIT Division of Health Sciences and Technology (HST) and MIT's Department of Electrical Engineering and Computer Science, and HST postdoctoral associate Salman Khetani describe their model liver tissue and its behavior in the November 18 online issue of Nature Biotechnology.

To build these model livers, Khetani uses micropatterning technology—the same technology used to place tiny copper wires on computer chips—to precisely arrange human liver cells and other supporting cells on a plate. Khetani adapted this method from Bhatia’s early work as an HST graduate student building micropatterned co-cultures of rat liver cells and supporting cells.

Such precisely arranged cells results in what Bhatia calls a “high-fidelity tissue model” because it so closely mimics the behavior of a human liver. For example, each model “organ” secretes the blood protein albumin, synthesizes urea, and produces the enzymes necessary to break down drugs and toxins.

To predict how close their model tissue is to real liver tissue, which has over 500 different functions, they also evaluated its gene expression profiles, measures of the levels of gene activation in the tissues. They found that these profiles are very similar to those of fresh liver cells, “giving us confidence that other [liver] functions are preserved,” said Khetani.

For drug testing purposes, this affinity to the human liver allows each colony to provide a window into the human liver’s response to a drug without having to expose human patients to the drug in a clinical trial, said Bhatia.

Further, because the engineered tissue lives for so long, it has the potential to make new types of toxicity tests possible. For instance, it opens the door to testing the effects of long-term drug use akin to taking one pill a day over multiple weeks. It also will allow more extensive testing of drug-drug interactions.

In addition to being a good biological model, the engineered tissue is designed to be seamlessly integrated into an industrial pharmaceutical science setting.

To mass-produce plates of the miniature liver models, Khetani relies on a technique called soft lithography. This technique fashions a reusable micropatterned rubber stencil from a silicon master. Each stencil contains an array of 24 wells, and each well contains a matrix of 37 tiny holes. Khetani “peels and sticks” the stencil onto plates and places the liver cells into the holes, patterning over 888 miniature model livers across the microwells in a matter of minutes.

In tests of drugs with a range of well-known toxicity levels, assays (chemical detection tests) on the miniature liver models showed the expected levels of toxicity. “Our platform was able to predict the relative toxicity of these drugs as seen in the clinic,” said Khetani. For instance, troglitazone, a drug withdrawn from the market by the FDA due to liver toxicity, showed toxicity levels much higher than its FDA-approved analogues, Rosiglitazone and Pioglitazone.

The model uses a fraction of the costly human liver cells used in other test platforms and can be assembled using frozen cells. Moreover, the expanded toxicity testing capabilities have the potential to allow drug developers to identify toxicity earlier in the development process, thereby avoiding the expense of investing in formulas that are bound to fail.

A startup company called Hepregen has licensed the technology and is working to introduce it into the pharmaceutical marketplace.

“My hope is that this new model will make drugs safer, cheaper, and better labeled,” said Bhatia.

Source: Massachusetts Institute of Technology

Related stories:

Marine organisms could hold the secret to reducing cancer
Research into why a tea derived from an ancient crop from the western Pacific could be responsible for reducing the risk of cancer, is being conducted by Aberdeen experts.
Skin flaps deliver cancer-fighting therapy, ASPS study reveals
Using gene therapy, plastic surgeons have delivered cancer fighting proteins through skin flaps placed on cancerous tumors on rats with a 79 percent reduction in tumor volume, according to a study in the May issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons (ASPS). This new delivery technique, which has yet to be tested in humans, did not cause toxicity in the body of rats; however, administering the same anti-tumor agent intravenously in humans has previously been shown to cause liver damage.
Studies test new approaches to islet transplantation
Researchers from 11 medical centers in the United States, Canada, Sweden, and Norway have begun testing new approaches to transplanting clusters of insulin-producing islets in adults with difficult-to-control type 1 diabetes. The clinical studies, funded by the National Institutes of Health (NIH), will determine whether changes to current methods of islet transplantation lead to improved, long-lasting control of blood glucose with fewer side effects.
Turtle studies suggest health risks from environmental contaminants
The same chemicals that keep food from sticking to our frying pans and stains from setting in our carpets are damaging the livers and impairing the immune systems of loggerhead turtles—an environmental health impact that also may signal a danger for humans.
Nanotechnology Advances Brain Cancer Detection and Therapy
Brain cancer is one of the most aggressive and lethal of malignancies, made even more difficult to treat by the fact that most anticancer drugs have a hard time even getting to the tumors. Now, studies by three different groups of researchers show that targeted nanoparticles hold promise for solving this delivery problem.
New Nanotube Findings Give Boost to Potential Biomedical Applications
Carbon nanotubes have shown real promise as highly accurate vehicles for delivering antitumor agents into malignant cells, but a dearth of data about what happens to the tubes after they discharge their medical payloads has been a major stumbling block to progress. Now, two studies at the Center for Cancer Nanotechnology Excellence Focused on Therapy Response have revealed some reassuring answers after months of tracking the tiny tubes inside mice.
A fruit a day may keep Alzheimer's away
Eating more apples, bananas and oranges just may help stave off such neurodegenerative diseases as Alzheimer's and Parkinson's, suggests a new Cornell study published online in the Journal of Food Science.
Researchers investigate links between prostate, cadmium, zinc
Cadmium exposure is a known risk factor for prostate cancer, and a new University of Rochester study suggests that zinc may offer protection against cadmium.

News discussion:

General Science news